International Markets

Growing Strength in the International Arena

One of Abdi İbrahim's greatest goals is to become an important global player by continuing its growth in international markets. The company is expanding its activities abroad through new products and organizations in strategic markets such as Kazakhstan, Algeria, Iraq, Georgia, Azerbaijan, Albania, Bosnia and Herzegovina, Portugal, Tunisia, Qatar, United Arab Emirates and Saudi Arabia. Meanwhile, it aims to increase sales volumes in other countries by focusing on products and portfolio. Abdi İbrahim increases its export volume through licensed sales activities all across the world, particularly in Europe and Canada.

The company continues its growth in 12 countries except for Turkey, where it has ongoing sales and marketing organizations, with a total field and head office staff of 580. 

Increased Collaboration

With each passing year, Turkey’s leading and innovative company Abdi İbrahim continues to increase its strength in countries in which it is present. The company enters into sales & marketing and production partnerships in its regions for reference products from around the world, with new collaborations being introduced every year.

In line with its growth policies concerning international markets, Abdi İbrahim wants to reinforce its presence in Canada, Europe, the CIS countries, North Africa and the Middle East, and accordingly, it has signed license agreements for product marketing with some of the world’s leading pharmaceutical companies, such as Sanofi, Mylan, and Sandoz.

Abdi İbrahim has commenced production in the most advanced production facility of Kazakhstan, where it operates through its affiliate Abdi İbrahim Global Pharm (AIGP) established in 2012, and has become the only long-term supplier of diabetes and hepatology products as per an agreement with the state procurement agency, SK Pharmacy. Thus, for the first time, Abdi İbrahim has started producing medicines outside of Turkey, and in 2016, began exporting from Kazakhstan to neighboring countries. The volume of exports are planned to increase in the years ahead.

Abdi İbrahim also aims to drive up its activities in the Middle East and North African markets. In this regard, the company has entered into a strategic cooperation in Saudi Arabia in 2014 for the production, sales, and marketing of Abdi İbrahim products. Also in 2014, the company has signed a partnership agreement with Remede Pharma, one of the leading companies in the country, in order to consolidate its presence in Algeria. This cooperation has led to the establishment of Abdi İbrahim Remede Pharm (AIRP), as well as the start of investments for the most advanced production facility in the pharmaceutical sector of the country. The facility, which will enter into service in 2017, will be the stepping stone for significant developments in the field of production. At the same time, the company has obtained its first biosimilar product license in Algeria in 2015, and launched the product in 2016.

Continuing its activities in Europe with Abdi Farma based in Portugal, Abdi İbrahim heals the lives it touches in the EU as well, especially in Portugal, Germany, the Netherlands, Spain, Italy, France, the UK, the Czech Republic, Poland, Bulgaria, with a variety of medicines used in the treatment of Alzheimer’s, PAH, chronic pain, osteoporosis, asthma, Parkinson’s, and secondary hyperparathyroidism in dialysis patients.

In the upcoming period, Abdi İbrahim will continue its growth in the European market with innovative combination medicines for stomach and hearth health, and two respiration agents, which are set to become the first generics on the market.


© 2016-2018 Abdi İbrahim İlaç Sanayi ve Tic A.Ş.
The information provided on this site is not intended as an advice. Information provided should be discussed with your healthcare professional.
Phone: 0212 366 8400